Compare KB Financial Group, Inc. (KB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Novavax Inc — how do they compare? KB Financial Group, Inc. trades at $117.53 (market cap $42.79B), while Novavax Inc trades at $7.96 (market cap $1.30B). The key difference: KB Financial Group, Inc. is far larger — about 32.9× Novavax Inc's market cap, and KB Financial Group, Inc. pays a 2.6% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| KB | NVAX | |
|---|---|---|
Market Cap | $42.79B | $1.30B |
Sector | Financials | Health |
52-Week High | $124.01 | $11.19 |
52-Week Low | $77.50 | $6.22 |
Dividend Yield | 2.6% | — |
Enterprise Value | — | $879.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $124.01, up 2.22% today, with a bullish technical outlook from moving averages and recent momentum. The stock shows strong fundamentals, with net income margin at 27.82% and a P/E ratio of 11.03, indicating potential undervaluation. Recent earnings beats in Q1 and Q2 2026, alongside positive news coverage on diversification efforts, support investor confidence.
The outlook for KB is positive, driven by earnings growth and strategic expansion into non-banking segments. Risks include volatile cash flow trends and high interest expenses. Analyst consensus is mixed but leans hold, with institutional interest steady. Upside potential exists if profitability trends continue, though macroeconomic factors could pressure performance.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
